Breast cancer continues to affect millions worldwide, not just as statistics, but as mothers, sisters, daughters, and friends. Its biological complexity and diverse subtypes make therapy development especially challenging, particularly for metastatic disease, the leading cause of breast cancer mortality.

BioDuro’s CDX (Cell-Derived Xenograft) model platform offers a comprehensive library of preclinical breast cancer models that reflect real-world tumor heterogeneity. These models enable researchers to:

• Investigate metastasis mechanisms in clinically relevant systems
• Evaluate targeted therapies across key breast cancer subtypes
• Accelerate translation from lab to clinic with improved predictability

By bridging preclinical and clinical insights, our platform supports smarter, faster, and more translatable drug discovery for breast cancer therapies.

Read the full article:
Science in Action: Translating Breast Cancer Drug Discovery Through Smarter Preclinical Models →

*Guest blog by BioDuro. If you would like to submit a blog please email [email protected]